Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?

Detalhes bibliográficos
Autor(a) principal: Romão, Vasco C.
Data de Publicação: 2017
Outros Autores: Vital, Edward M., Fonseca, João Eurico, Buch, Maya H.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/51574
Resumo: © The Author(s). 2017. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
id RCAP_4600d38336481d655f7fcd48634fed38
oai_identifier_str oai:repositorio.ul.pt:10451/51574
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?Biological therapyBiomarkersPersonalised therapyResponse predictorsRheumatoid arthritis© The Author(s). 2017. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.Individualising biologic disease-modifying anti-rheumatic drugs (bDMARDs) to maximise outcomes and deliver safe and cost-effective care is a key goal in the management of rheumatoid arthritis (RA). Investigation to identify predictive tools of bDMARD response is a highly active and prolific area of research. In addition to clinical phenotyping, cellular and molecular characterisation of synovial tissue and blood in patients with RA, using different technologies, can facilitate predictive testing. This narrative review will summarise the literature for the available bDMARD classes and focus on where progress has been made. We will also look ahead and consider the increasing use of 'omics' technologies, the potential they hold as well as the challenges, and what is needed in the future to fully realise our ambition of personalised bDMARD treatment.Springer NatureRepositório da Universidade de LisboaRomão, Vasco C.Vital, Edward M.Fonseca, João EuricoBuch, Maya H.2022-03-02T16:51:53Z20172017-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/51574engArthritis Research & Therapy (2017) 19:2391478-635410.1186/s13075-017-1445-31478-6362info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:56:22Zoai:repositorio.ul.pt:10451/51574Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:02:50.969546Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
title Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
spellingShingle Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
Romão, Vasco C.
Biological therapy
Biomarkers
Personalised therapy
Response predictors
Rheumatoid arthritis
title_short Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
title_full Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
title_fullStr Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
title_full_unstemmed Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
title_sort Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
author Romão, Vasco C.
author_facet Romão, Vasco C.
Vital, Edward M.
Fonseca, João Eurico
Buch, Maya H.
author_role author
author2 Vital, Edward M.
Fonseca, João Eurico
Buch, Maya H.
author2_role author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Romão, Vasco C.
Vital, Edward M.
Fonseca, João Eurico
Buch, Maya H.
dc.subject.por.fl_str_mv Biological therapy
Biomarkers
Personalised therapy
Response predictors
Rheumatoid arthritis
topic Biological therapy
Biomarkers
Personalised therapy
Response predictors
Rheumatoid arthritis
description © The Author(s). 2017. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
publishDate 2017
dc.date.none.fl_str_mv 2017
2017-01-01T00:00:00Z
2022-03-02T16:51:53Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/51574
url http://hdl.handle.net/10451/51574
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Arthritis Research & Therapy (2017) 19:239
1478-6354
10.1186/s13075-017-1445-3
1478-6362
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Nature
publisher.none.fl_str_mv Springer Nature
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134579072696320

Registros relacionados